German pharmaceutical giant Boehringer Ingelheim has entered into a collaboration and licensing agreement with UK-based ExpressionEdits. The deal leverages ExpressionEdits’ Genetic Syntax Engine technology to advance gene therapy development.
Technology Details
The Genetic Syntax Engine is a proprietary AI-powered platform. It uses optimized introns to enhance gene expression without altering the underlying genetic sequence. This technology is designed to increase the effectiveness and accuracy of gene therapy as well as protein expression.
Agreement Terms
Under the agreement, Boehringer Ingelheim will obtain the use rights to the Genetic Syntax Engine technology. In return, it will pay ExpressionEdits an undisclosed upfront payment. Additionally, Boehringer Ingelheim will make potential pre – clinical, clinical, and commercial milestone payments.
Expansion of Application Field
ExpressionEdits’ intronization approach, which enhances therapeutic gene expression by restoring introns, will see its application field expanded. Thanks to the deal, it will move beyond protein – based therapeutics into gene therapies.-Fineline Info & Tech
